Contribution of cerebral amyloid angiopathy to Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 1, 2004, Pages 1-4

  Love, S ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ALZHEIMER DISEASE; AUTOPSY; BRAIN BIOPSY; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL FEATURE; COGNITIVE DEFECT; EDITORIAL; GENE FREQUENCY; GENETIC RISK; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; NEUROPSYCHIATRY; NEURORADIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOPSY; CEREBRAL AMYLOID ANGIOPATHY; DIAGNOSIS, DIFFERENTIAL; HUMANS; RISK FACTORS;

EID: 0347755563     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (69)

1. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pothoanatomical study. Ann Neurol 1986;19:253-62.
2. Scheltens P, Barkhof F, Leys D, et al. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 1995;45:883-8.
3. Tomimoto H, Akiguchi I, Akiyama H, et al. Vascular changes in white matter lesions of Alzheimer's disease. Acta Neuropathol 1999;97:629-34.
4. Catani M, Cherubini A, Howard R, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315-17.
5. De Stefano N, Mortilla M, Federico A. Proton magnetic resonance spectroscopy of the brain in dementia. Ital J Neurol Sci 1999;20:S258-64.
6. DeCarli C, Grady CL, Clark CM, et al. Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. J Neurol Neurosurg Psychiatry 1996;60:158-67.
7. Hanyu H, Sakurai H, Iwamoto T, et al. Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. J Neurol Sci 1998;156:195-200.
8. Rose SE, Chen F, Chalk JB, et al. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 2000;69:528-30.
9. Bennett DA, Gilley DW, Wilson RS, et al. Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease. J Neurol 1992;239:186-90.
10. Bennett DA, Gilley DW, Lee S, et al. White matter changes: neurobehavioral manifestations of Binswanger's disease and clinical correlates in Alzheimer's disease. Dementia 1994;5:148-52.
11. Hirono N, Kitagaki H, Kazui H, et al. Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke 2000;31:2182-8.
12. O'Brien J, Perry R, Barber R, et al. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann NY Acad Sci 2000;903:482-9.
13. Parnetti L, Tarducci R, Presciutti O, et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 1997;97:9-14.
14. Amar K, Bucks RS, Lewis T, et al. The effect of white matter low attenuation on cognitive performance in dementia of the Alzheimer type. Age Ageing 1996;25:443-8.
15. Bronge L, Fernaeus SE, Blomberg M, et al. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement Geriatr Cogn Dis 1999;10:89-96.
16. Olichney JM, Hansen LA, Lee JH, et al. Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer's disease. Ann NY Acad Sci 2000;903:138-43.
17. Premkumar DR, Cohen DL, Hedera P, et al. Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148:2083-95.
18. Barber R, Gholkar A, Scheltens P, et al. Apolipoprotein E ε4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961-5.
19. Doody RS, Azher SN, Haykal HA, et al. Does APO ε4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;69:668-71.
20. Hirono N, Yasuda M, Tanimukai S, et al. Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke 2000;31:1263-8.
21. Sawada H, Udaka F, Izumi Y, et al. Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;68:653-6.
22. Kawamura J, Meyer JS, Terayama Y, et al. Cerebral white matter perfusion in dementia of Alzheimer type. Alz Dis Assoc Dis 1991;5:231-9.
23. Lopez OL, Becker JT, Rezek D, et al. Neuropsychiatric correlates of cerebral white-matter radiolucencies in probable Alzheimer's disease. Arch Neurol 1992;49:828-34.
24. Blennow K, Wallin A, Uhlemann C, et al. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991;83:187-93.
25. Yamada M, Tsukagoshi H, Otomo E, et al. Cerebral amyloid angiopathy in the aged. J Neurol 1987;234:371-6.
26. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983;14:924-8.
27. Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 1986;49:1221-6.
28. Chalmers K, Wilcock GK, Love S. APOE ε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol 2003;29:231-8.
29. Love S, Nicoll JA, Wilcock GK. APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 2003;14:1535-6.
30. Cadavid D, Mena H, Koeller K, et al. Cerebral β amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 2000;59:768-73.
31. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996;46:1592-6.
32. Olichney JM, Hansen LA, Hofstetter CR, et al. Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol 2000;57:869-74.
33. Gray F, Dubas F, Roullet E, et al. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985;18:54-9.
34. Loes DJ, Biller J, Yuh WT, et al. Leukoencephalopathy in cerebral amyloid angiopathy: MR imaging in four cases. Am J Neuroradiol 1990;11:485-8.
35. Yoshimura M, Yamanouchi H, Kuzuhara S, et al. Dementia in cerebral amyloid angiopathy: a clinicopathological study. J Neurol 1992;239:441-50.
36. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 2002;14:161-6.
37. Crawford F, Suo Z, Fang C, et al. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp Neurol 1998;150:159-68.
38. Paris D, Town T, Parker TA, et al. Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's β-amyloid peptide. Neurosci Lett 1998;256:73-6.
39. de Figueiredo RJ, Oten R, Su J, et al. Amyloid deposition in cerebrovascular angiopathy. Ann NY Acad Sci 1997;826:463-71.
40. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann NY Acad Sci 1999;893:113-25.
41. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-35.
42. Weller RO, Massey A, Kuo YM, et al. Cerebral amyloid angiopathy: accumulation of Aβ in interstitial fluid drainage pathways in Alzheimer's disease. Ann NY Acad Sci 2000;903:110-7.
43. Wyss-Coray T, Lin C, Yan F, et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat Med 2001;7:612-18.
44. Chalmers K, Wilcock GK, Love S. Cerebral amyloid angiopathy in Alzheimer's disease does not influence neocortical synaptic density or subcortical white matter accumulation of β-amyloid precursor protein. Neuropathol Appl Neurobiol 2003;29:184.
45. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33.
46. Preston SD, Steart PV, Wilkinson A, et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol Appl Neurobiol 2003;29:106-17.
47. Weller RO, Yow HY, Preston SD, et al. Cerebrovascular disease is a major factor in the failure of elimination of Aβ from the aging human brain: implications for therapy of Alzheimer's disease. Ann NY Acad Sci 2002;977:162-8.
48. Shibato M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.
49. Monro OR, Mackic JB, Yamada S, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002;23:405-12.
50. Wyss-Coray T, Lin C, Sanan DA, et al. Chronic overproduction of transforming growth factor-β1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 2000;156:139-50.
51. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6.
52. Luterman JD, Haroutunian V, Yemul S, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000;57:1153-60.
53. Chao CC, Ala TA, Hu S, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1994;1:433-6.
54. Chao CC, Hu S, Frey WH 2nd, et al. Transforming growth factor β in Alzheimer's disease. Clin Diagn Lab Immunol 1994;1:109-10.
55. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-52.
56. Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann NY Acad Sci 2002;977:37-44.
57. Yamada M, Sodeyama N, Itoh Y, et al. Association of neprilysin polymorphism with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2003;74:749-51.
58. Brooks WS, Kwok JB, Kril JJ, et al. Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. Brain 2003;126:783-91.
59. Tabira T, Chui de H, Nakayama H, et al. Alzheimer's disease with spastic paresis and cotton wool type plaques. J Neurosci Res 2002;70:367-72.
60. Steiner H, Revesz T, Neumann M, et al. A pathogenic presenilin-1 deletion causes abberrant Aβ42 production in the absence of congophilic amyloid plaques. J Biol Chem 2001;276:7233-9.
61. O'Riordan S, McMonagle P, Janssen JC, et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002;59:1108-10.
62. Verkkoniemi A, Kalimo H, Paetau A, et al. Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 2001;60:483-92.
63. Houlden H, Baker M, McGowan E, et al. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-β concentrations. Ann Neurol 2000;48:806-8.
64. Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E ε2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716-21.
65. McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann NY Acad Sci 2000;903:176-9.
66. Greenberg SM, Cho HS, O'Donnell HC, et al. Plasma β-amyloid peptide, transforming growth factor-β1, and risk for cerebral amyloid angiopathy. Ann NY Acad Sci 2000;903:144-9.
67. Knudsen KA, Rosand J, Karluk D, et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-9.
68. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid anqiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418-22.
69. McCarron MO, Nicoll JA, Love S, et al. Surgical intervention, biopsy and APOE genotype in cerebral amyloid angiopathy-related haemorrhage. Br J Neurosurg 1999;13:462-7.